Obesity was once medicine’s Cinderella subject with some questioning whether the condition should even be viewed as a biological disorder. But the arrival of a new class of appetite-suppressing drugs such as Ozempic and Wegovy has transformed obesity treatment into the most scientifically exciting and commercially lucrative area of healthcare.
These drugs lead to dramatic weight loss, are shifting perceptions and, according to a series of results announced at the European Congress on Obesity (ECO) in Málaga this week, promise health benefits that extend far beyond weight management.
